FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912237968> ?p ?o ?g. }

• W2912237968 abstract "To the Editor: This letter presents some suggestions of possible therapies for sickle cell disease that are based on interpretations of presumed effects of different substrates that alter the cellular levels of ATP. A prevailing idea is that the shrinkage of sickle cells is the result of an increase in intracellular Ca that turns on the Ca-activated K channel (Gardos channel1) which causes the cells to shrink and become sickled. The presumption is that the sickled cells can lead to capillary flow blockage resulting in a patient's clinical crisis. If the cellular shrinkage could be prevented the ensuing crisis might be mitigated. The approaches discussed below might be candidates that keep the cells from shrinking. Walter Wilbrandt reported in 19372 that red blood cells exposed to fluoride shrink as a result of the loss of K. This type of K+ loss was later shown to be by the Gardos channel. Importantly, he found that the shrinkage of the cells could be prevented by the addition of pyruvate to the medium. It occurred to me that the effect of pyruvate might be due to the synthesis of ATP by the cell's redox system, which prevented the activity of the Gardos channel. This inhibition could occur by preventing the accumulation of cellular Ca by ATP acting to stimulate the cell's Ca pump.3 This interpretation has yet to be tested. A second possible approach emanates from a paper from the Agios Pharmaceuticals, Inc.,4 in which they report that their drug, AG-348, significantly increased the intracellular concentration of ATP in normal cells. Obviously, if the idea that the action of pyruvate was via ATP, then the AG-348 drug is a better choice over pyruvate. A third possibility arose with the publication of a clinical trial of testing the effect of glutamine therapy on sickle cell patients.5 It is thought that the effect of glutamine is to act on the cell's redox system, NAD/NADH. If this is so, then a possible result is that this could increase the cell's ATP concentration by stimulating glycolysis. This could mimic the effect of pyruvate considered above. It is obvious that the underlying suggestion in all of the above approaches relies on the central role of cellular ATP. It seems straight forward that these effects are easily testable on sickle cells as a function of aerobic/anaerobic conditions. Perhaps these types of results will be soon forthcoming. The author declare that they have no financial conflicts or conflicts of interest with the contents of this article." @default.
• W2912237968 created "2019-02-21" @default.
• W2912237968 creator A5006060078 @default.
• W2912237968 date "2019-02-14" @default.
• W2912237968 modified "2023-09-26" @default.
• W2912237968 title "Erythrocyte ATP, a possible therapeutic approach for sickle cell disease" @default.
• W2912237968 cites W2739917247 @default.
• W2912237968 cites W2883955692 @default.
• W2912237968 doi "https://doi.org/10.1002/ajh.25419" @default.
• W2912237968 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30681180" @default.
• W2912237968 hasPublicationYear "2019" @default.
• W2912237968 type Work @default.
• W2912237968 sameAs 2912237968 @default.
• W2912237968 citedByCount "2" @default.
• W2912237968 countsByYear W29122379682021 @default.
• W2912237968 countsByYear W29122379682023 @default.
• W2912237968 crossrefType "journal-article" @default.
• W2912237968 hasAuthorship W2912237968A5006060078 @default.
• W2912237968 hasBestOaLocation W29122379681 @default.
• W2912237968 hasConcept C126322002 @default.
• W2912237968 hasConcept C1491633281 @default.
• W2912237968 hasConcept C185592680 @default.
• W2912237968 hasConcept C2777208419 @default.
• W2912237968 hasConcept C55493867 @default.
• W2912237968 hasConcept C71924100 @default.
• W2912237968 hasConcept C79879829 @default.
• W2912237968 hasConceptScore W2912237968C126322002 @default.
• W2912237968 hasConceptScore W2912237968C1491633281 @default.
• W2912237968 hasConceptScore W2912237968C185592680 @default.
• W2912237968 hasConceptScore W2912237968C2777208419 @default.
• W2912237968 hasConceptScore W2912237968C55493867 @default.
• W2912237968 hasConceptScore W2912237968C71924100 @default.
• W2912237968 hasConceptScore W2912237968C79879829 @default.
• W2912237968 hasIssue "5" @default.
• W2912237968 hasLocation W29122379681 @default.
• W2912237968 hasLocation W29122379682 @default.
• W2912237968 hasOpenAccess W2912237968 @default.
• W2912237968 hasPrimaryLocation W29122379681 @default.
• W2912237968 hasRelatedWork W184568438 @default.
• W2912237968 hasRelatedWork W2001323044 @default.
• W2912237968 hasRelatedWork W2012202237 @default.
• W2912237968 hasRelatedWork W2061347603 @default.
• W2912237968 hasRelatedWork W2093183459 @default.
• W2912237968 hasRelatedWork W2402644831 @default.
• W2912237968 hasRelatedWork W2743616272 @default.
• W2912237968 hasRelatedWork W2748952813 @default.
• W2912237968 hasRelatedWork W2899084033 @default.
• W2912237968 hasRelatedWork W4224941751 @default.
• W2912237968 hasVolume "94" @default.
• W2912237968 isParatext "false" @default.
• W2912237968 isRetracted "false" @default.
• W2912237968 magId "2912237968" @default.
• W2912237968 workType "article" @default.